Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Podcast website:
http://www.podcast.net/tag/wallstreetreporter
Ann
DNAP interviews by Wall Street Podcast on several occasions:
http://smallcapstocksblog.com/2006_08_13_archive.html
Just connecting the dots.......
Ann
This Drug Conference is a link for DNAP:
http://www.wallstreetreporter.com/sdc/
Ann
Altar:
Again, I will click my beads for you! - lol
Ann
Altar:
Me thinks you fret too much! - lol
Relax, and try to have a nice weekend.
Take care,
Ann
Good job, 9car!
Ann
9car:
The photo almost looks like a "mock up" of a bldg. Lol - It's one of the angles, I know. But, it's ok - we're moving forward - IMO
Take care,
Ann
"Access to the database..."
Thank you, johnny!
Take care,
Ann
Lost it, sorry
Ann
Jeb Bush satements:
http://www.bradenton.com/mld/bradenton/news/local/16268648.htm
Ann
Have Merk/Moffit found cure?
http://www.tbo.com/news/money/MGBXGXEN2WE.html
Ann
Sorry - will try to post
Merk/Moffitt join forces:
com/2006/12/19/Tampabay/Moffitt__Merck_join_f.shtml
Ann
Bag:
OT:
"He'll be back!"
Warts don't go away that easy - lol
Take care,
Ann
If all comes into fruition, any bets Tony Frudakis will be awarded the Nobel Peace Prize?
I can dream...can't I?
Ann
"And so, gentle reader, we bring this latest experiment to a close. I am sure that you will agree with me that it has been an excellent validation of my original premise."
Sounds like Frog's "farewell address."
Rigot!
Ann
DNAP Live conference - don't know if we heard this one - if so, no harm done:
http://biz.yahoo.com/cc/5/75735.html
Ann
Frog:
"LOL "Plop"
Do frogs grasp for straws?
Ann
Stockhldr:
"copy and paste link on browser"
I did copy and paste link on browser - and it brought up a blank page and "This page is unavailable."
Ann
An overview of USFl. Health Center Facility & location of Lee Moffitt:
http://hsc.usf.edu/nocms/global_files/images/pubaff/map_lg.jpg
Ann
"Said Dalton: "Rather than just blind treatment and everybody gets the same thing, each individual will have tailor-made therapies on their unique profile. I'm not talking decades. I'm talking a few years."
State and local governments contributed more than $35 million to get the collaboration started. Merck declined to specify the amount the company is investing in the partnership.
Moffitt spokeswoman Michelle Foley said the venture is part of a $20 million research program. The institute will contribute $1 million annually to the venture for five years. Moffitt, a nonprofit based in the University of South Florida, is Florida's only comprehensive cancer research center."
Ann
Jebb Bush announcement:
http://www.bradenton.com/mld/bradenton/business/16269581.htm
Ann
Re: Moffitt/Merck:
"It is through public-private partnerships like this one that we believe we can advance the discovery, translation and delivery of much-needed personalized therapies for cancer and other diseases," said Dr Stephen Friend, executive vice president, Oncology and Neuroscience, at Merck."
Ann
Stockhldr:
"I got the words "Merk invested a significant amount" from the link I provided."
The link you provided doesn't work.
Ann
Virgil - sorry, sir -
Ann
Viril:
I agree with your opinion re: DNAP's website
DNAP could start by inquiring as to who designed the Trace Genetics web site, for example, which in my opinion is more professionally layed out or find oher examples of professionally designed web sites. By the looks of it these past years, I don't think this was primary on their minds, but, they would be smart to develop our co. towards this "creative" goal.
Presentation is important and in many ways effective - realistically and subliminally. It's advertising which, not only speaks for itself visually - but, it sells!!
If someone ever designs a more prestigious website for DNAP, I will be much more impressed with my investment! Let's hope and it's -JMHO
Take care,
Ann
Virgil:
It could look more streamlined & prestigious!
Take care,
Ann
Gunnabe:
And, perhaps - DNAP is building their Pharmaceuticals website...
we'll see...that has to happen sooner or later!
Ann
Gunnabe:
Yes, interesting. They could be revising and updating the existing site info.
Ann
Gunnabe:
"i can't connect to dnag's home page or ancestrybydna web site"
Wonder if there is a lot of traffic on those sites?
Take care,
Ann
Lynn Peavey site for ordering DNA Witness kits:
http://www.lynnpeavey.com/product_info.php?manufacturers_id=&products_id=804
Ann
Stock:
Try Empting your cache files and defragment your C Drive.
Ann
You got it, Bag! - Ann
Bag: FYI
"Warfarin is a very widely used drug, it's been around for 50 years and it has adverse events associated with it."
If the warfarin studies are successful, patients will start demanding personalized medicine, he predicted. Insurers will, too, if the Medco study proves it saves money and protects patients."
Ann
DNAPrint Technology Featured In “Nature” Journal Review And Upcoming Textbook
DNAPrint genomics (OTCBB: “DNAP”) of Sarasota, FL (the “Company”) announces today that its ANCESTRYbyDNA™ 2.5 product will be featured in a review article to be published next month in the journal “Nature Reviews”. The article will focus on the growing interest in personal anthropology, and will highlight the uniqueness of DNAPrint’s role in this growing market. The article represents the first discussion of the Company’s proprietary BioGeographical Ancestry (BGA) admixture test in the peer-reviewed literature.
In addition, at the invitation of Academic Press Publishers, DNAPrint’s Chief Scientific Officer has agreed to co-author a textbook on the history, molecular genetics, mathematics and practice of molecular photo fitting, entitled “Molecular Photo fitting: Predicting Ancestry and Phenotype using DNA”. Dr. Mark Shriver, a co-author of the Nature Review article, was invited by DNAPrint to join the project as a co-author. The Company expects the work, targeted for publication March 1, 2006, to serve as the interface between the Company’s unique pharmacogenomics/forensics platform and the scientific community.
Ann
It's just that your posts are always a little over-zealous...or disproportionate, to say the least!
Ann
Sorry, Frog, couldn't resist - based on todays AOL News release:
"At least five frogs have died in Japan's first confirmed cases of a fungal infection linked to sharp reductions in amphibians in other parts of the world, an expert said Friday.
The discovery prompted animal and research groups in Japan to jointly declare an emergency, urging frog owners to contact veterinarians immediately for any abnormalities."
Should we discover those abnormalities to occur in you, need we be concerned? Just wondering and JMHO...
Ann
View DNAP's E-Symposium:
http://megansrootsworld.blogspot.com/2006/07/you-can-still-view-dnaprints-e.html
Ann
On your mark...get set...
Personalized medicine kick off...
Updated:2007-01-12 15:03:44
DNA Tests to Determine Warfarin Dose
By LINDA A. JOHNSON
AOL News Release AP
TRENTON, N.J. (Jan. 12) - Personalized medicine, the tailored treatments that a few patients now get based on their own DNA, is finally headed for the masses: the many heart patients at risk of deadly blood clots.
At least 2 million Americans with an abnormal, clot-triggering heart rhythm take the pill warfarin, also sold as Coumadin.
Getting too little can lead to a stroke, and too much can cause life-threatening bleeding. To find the right dose for each patient, doctors use trial and error - and the errors lead to tens of thousands of hospitalizations and deaths every year.
Starting this month, about 1,000 patients who have a condition known as atrial fibrillation will take part in a project that will match their Coumadin dose to their specific genetic needs.
This genetic fingerprinting should single out the many people whose bodies break down warfarin faster or slower than normal, and their doctors can immediately adjust their dosage to prevent dangerous complications.
"Twenty to 30 percent of people are either very fast or very slow" to metabolize many drugs but don't know it, said Dr. Robert Epstein, chief medical officer at prescription benefit manager Medco Health Solutions of Franklin Lakes, N.J., which is collaborating in the effort with the Mayo Clinic, based in Rochester, Minn.
Meanwhile, the federal government and researchers at Harvard University and elsewhere have begun or are planning similar studies.
Epstein and other experts say the warfarin projects comprise the first broad use of personalized medicine, or targeted therapy, in which a person's genetic makeup is used to pick the best medicine or dose. This approach essentially adjusts for differences in body chemistry that explain why one pain reliever or allergy pill works great for you but not for your mom.
"It's a big deal," said Edward Abrahams of the Personalized Medicine Coalition, which includes industry, government and patient advocacy groups as well as insurers and research centers. "Warfarin is a very widely used drug, it's been around for 50 years and it has all these adverse events associated with it."
If the warfarin studies are successful, patients will start demanding personalized medicine, he predicted. Insurers will, too, if the Medco study proves it saves money and protects patients.
That's fairly likely, given Medco data showing that if patients have their warfarin dose changed more than once - meaning doctors didn't get it right the first two tries - their risk of being hospitalized for complications jumps from 20 percent to 31 percent.
Epstein said he's hit "a home run" with his pitch to get employers and insurance companies sponsoring the prescription plans to join the study.
"Everyone we've talked to unanimously was in," said Epstein, who expects the reduction in medical costs will be triple the test price of a few hundred dollars per patient.
He noted a couple dozen companies already are developing commercial tests for variations in the two genes crucial in warfarin dosing, the ones in the new studies. However, sales have been slow for the only government-approved testing device, Roche's Amplichip, which covers numerous gene variations.
A November 2006 report by the American Enterprise Institute-Brookings Joint Center predicts using genetic information to prescribe warfarin would save an estimated $1.1 billion in U.S. health care spending each year, while preventing about 17,000 strokes and 85,000 serious bleeding incidents.
Bleeding complications alone kill about 8,000 people a year and are the No. 2 reason for medication-related ER visits, said Dr. Elizabeth Nabel, director of the National Heart, Lung, and Blood Institute. Still, warfarin is far better at preventing clots than aspirin or drugs like Plavix, which only affect part of the clotting system, she said.
But patients on warfarin must have blood drawn and tested repeatedly to see if it clots too fast or too slow, initially every week or more often.
"Most hospitals have a warfarin clinic, where people come in for adjustments," she noted.
So along with the Food and Drug Administration, her institute now is planning one or two large studies on personalizing warfarin dosing. The FDA also is poised to alter the package insert for warfarin to note that gene variations in some patients mean they need a lower dose than normal.
Meanwhile, five Harvard Medical School teaching hospitals just began a study including 500 warfarin patients to try to boost the percentage getting the optimal dose. Only about 60 percent do now, said Dr. Samuel Goldhaber, a Harvard cardiologist and professor.
At the Marshfield Clinic Research Foundation in Wisconsin, a new study will compare results for 250 patients getting warfarin through standard trial and error with 250 getting doses that are genetically based, said Dr. Michael Caldwell, who started the personalized medicine program there in 2000.
And in the one-year Medco project, DNA from more than 1,000 patients' blood samples will be shipped to the Mayo Clinic, which will do the genetic testing and send the results directly to the patient's doctor. Medco, which manages prescription benefits for one in five Americans, plans to use the results to speed up adoption of the strategy, according to Epstein.
The studies will produce different, but complementary information that can be pooled for a complete picture, Goldhaber said.
Dr. Franklyn Prendergast, director of Mayo's Center for Individualized Medicine, cautioned against assuming the results will be positive, because blood-clotting is a very complicated process.
However, he noted that doctors are now able to use gene tests to find the right treatments for patients with breast and lung cancer, leukemia and a rare brain cancer.
Uses in other areas of medicine, such as psychiatry, are generally limited to top academic medical centers, but likely will expand as research proves its value and testing becomes cheaper.
Dr. Eric Braverman, director of integrated medicine at Cabrini Medical Center in New York, said more research is needed to prove personalized medicine improves care, but studies so far show promise in areas from Alzheimer's to addiction and obesity. He predicted personalized medicine will one day be used to forecast a child's potential future health problems, such as heart disease, so that preventive diet and lifestyle changes can be made early.
As Prendergast put it: "The potential is unbelievable for doing good."
Ann
Good day to you, Bag.
Ann